Racial inequities and rare CFTR variants: Impact on cystic fibrosis diagnosis and treatment

IF 4.2 Q1 ENDOCRINOLOGY & METABOLISM Journal of Clinical and Translational Endocrinology Pub Date : 2024-04-20 DOI:10.1016/j.jcte.2024.100344
Malinda Wu , Jacob D. Davis , Conan Zhao , Tanicia Daley , Kathryn E. Oliver
{"title":"Racial inequities and rare CFTR variants: Impact on cystic fibrosis diagnosis and treatment","authors":"Malinda Wu ,&nbsp;Jacob D. Davis ,&nbsp;Conan Zhao ,&nbsp;Tanicia Daley ,&nbsp;Kathryn E. Oliver","doi":"10.1016/j.jcte.2024.100344","DOIUrl":null,"url":null,"abstract":"<div><p>Cystic fibrosis (CF) has been traditionally viewed as a disease that affects White individuals. However, CF occurs among all races, ethnicities, and geographic ancestries. The disorder results from mutations in the <em>CF transmembrane conductance regulator</em> (<em>CFTR</em>). Varying incidence of CF is reported among Black, Indigenous, and People of Color (BIPOC), who typically exhibit worse clinical outcomes. These populations are more likely to carry rare <em>CFTR</em> variants omitted from newborn screening panels, leading to disparities in care such as delayed diagnosis and treatment. In this study, we present a case-in-point describing an individual of Gambian descent identified with CF. Patient genotype includes a premature termination codon (PTC) (c.2353C&gt;T) and previously undescribed single nucleotide deletion (c.1970delG), arguing against effectiveness of currently available CFTR modulator-based interventions. Strategies for overcoming these two variants will likely include combinations of PTC suppressors, nonsense mediated decay inhibitors, and/or alternative approaches (e.g. gene therapy). Investigations such as the present study establish a foundation from which therapeutic treatments may be developed. Importantly, c.2353C&gt;T and c.1970delG were not detected in the patient by traditional <em>CFTR</em> screening panels, which include an implicit racial and ethnic diagnostic bias as these tests are comprised of mutations largely observed in people of European ancestry. We suggest that next-generation sequencing of <em>CFTR</em> should be utilized to confirm or exclude a CF diagnosis, in order to equitably serve BIPOC individuals. Additional epidemiologic data, basic science investigations, and translational work are imperative for improving understanding of disease prevalence and progression, <em>CFTR</em> variant frequency, genotype-phenotype correlation, pharmacologic responsiveness, and personalized medicine approaches for patients with African ancestry and other historically understudied geographic lineages.</p></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":null,"pages":null},"PeriodicalIF":4.2000,"publicationDate":"2024-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2214623724000152/pdfft?md5=5090e775b1523be2a90facba1ac9ddce&pid=1-s2.0-S2214623724000152-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical and Translational Endocrinology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2214623724000152","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Cystic fibrosis (CF) has been traditionally viewed as a disease that affects White individuals. However, CF occurs among all races, ethnicities, and geographic ancestries. The disorder results from mutations in the CF transmembrane conductance regulator (CFTR). Varying incidence of CF is reported among Black, Indigenous, and People of Color (BIPOC), who typically exhibit worse clinical outcomes. These populations are more likely to carry rare CFTR variants omitted from newborn screening panels, leading to disparities in care such as delayed diagnosis and treatment. In this study, we present a case-in-point describing an individual of Gambian descent identified with CF. Patient genotype includes a premature termination codon (PTC) (c.2353C>T) and previously undescribed single nucleotide deletion (c.1970delG), arguing against effectiveness of currently available CFTR modulator-based interventions. Strategies for overcoming these two variants will likely include combinations of PTC suppressors, nonsense mediated decay inhibitors, and/or alternative approaches (e.g. gene therapy). Investigations such as the present study establish a foundation from which therapeutic treatments may be developed. Importantly, c.2353C>T and c.1970delG were not detected in the patient by traditional CFTR screening panels, which include an implicit racial and ethnic diagnostic bias as these tests are comprised of mutations largely observed in people of European ancestry. We suggest that next-generation sequencing of CFTR should be utilized to confirm or exclude a CF diagnosis, in order to equitably serve BIPOC individuals. Additional epidemiologic data, basic science investigations, and translational work are imperative for improving understanding of disease prevalence and progression, CFTR variant frequency, genotype-phenotype correlation, pharmacologic responsiveness, and personalized medicine approaches for patients with African ancestry and other historically understudied geographic lineages.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
种族不平等和罕见的 CFTR 变异:对囊性纤维化诊断和治疗的影响
囊性纤维化(CF)历来被视为一种影响白人的疾病。然而,囊性纤维化在所有种族、民族和地域血统中都有发生。这种疾病是由 CF 跨膜传导调节器(CFTR)突变引起的。据报道,CF 在黑人、土著人和有色人种(BIPOC)中的发病率不尽相同,他们的临床治疗效果通常较差。这些人群更有可能携带新生儿筛查面板中遗漏的罕见 CFTR 变异,从而导致治疗上的差异,如诊断和治疗的延迟。在本研究中,我们介绍了一个案例,描述了一名被确认患有 CF 的冈比亚后裔。患者的基因型包括一个过早终止密码子(PTC)(c.2353C>T)和以前未曾描述过的单核苷酸缺失(c.1970delG),这不利于目前可用的基于 CFTR 调节剂的干预措施的有效性。克服这两种变异的策略可能包括 PTC 抑制剂、无意义介导衰变抑制剂和/或替代方法(如基因治疗)的组合。本研究等调查为开发治疗方法奠定了基础。重要的是,传统的CFTR筛查面板并未在该患者身上检测到c.2353C>T和c.1970delG,而传统的CFTR筛查面板包含了隐含的种族和民族诊断偏差,因为这些检测主要由在欧洲血统人群中观察到的突变组成。我们建议利用 CFTR 的下一代测序来确诊或排除 CF 诊断,以便公平地服务于 BIPOC 患者。更多的流行病学数据、基础科学研究和转化工作对于更好地了解非洲血统和其他历史上未被充分研究的地域血统患者的疾病患病率和进展、CFTR 变异频率、基因型与表型的相关性、药理反应性和个性化医疗方法至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
6.10
自引率
0.00%
发文量
24
审稿时长
16 weeks
期刊最新文献
Advances in nucleic acid delivery strategies for diabetic wound therapy Hyperandrogenic eumenorrheic NON-PCOS women versus women with PCOS after the GnRH-agonist stimulation test preceded by suppression of adrenal steroidogenesis with dexamethasone Correlation study of multiple inflammatory indices and vertebral compression fracture: A cross-sectional study Type 1 diabetes, celiac disease, and autoimmune thyroiditis autoantibodies in population-based type 2 diabetes patients Testosterone deficiency and chronic kidney disease
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1